ORYL Photonics launches breakthrough solubility and aggregation measurement platform
Life sciences
24 June 2025
ORYL F1, the first automated light-scattering platform for high-throughput solubility and aggregation measurement, launched at SLAS Europe 2025 in Hamburg. | © ORYL Photonics
Launched in Hamburg, the ORYL F1 marks a new milestone for EPFL spin-off ORYL Photonics, combining speed, precision, and sustainability for drug development.
ORYL Photonics has officially launched its first laboratory instrument, the ORYL F1, at the SLAS Europe Conference 2025 in Hamburg. The new platform enables automated, high-throughput measurement of solubility and aggregation of drug compounds, an essential process in the development of pharmaceuticals, biotherapeutics, and chemical formulations.
Developed from over a decade of research at EPFL, ORYL’s technology is based on second harmonic scattering, a highly sensitive laser-based technique that probes molecular structures and particle behavior in liquid environments. The ORYL F1 adapts this method to an automated 96- and 384-well format, allowing researchers to screen entire plates in as little as 15 minutes, up to 100 times faster than traditional HPLC systems and with significantly less sample consumption.
“This is the first solubility and aggregation platform designed for sensitivity, throughput, and minimal sample use,” said Orly Tarun, CEO and co-founder of ORYL Photonics. “It empowers researchers to generate more data, more sustainably, and make faster decisions in early-stage drug development.”
The instrument has already gained traction among major pharmaceutical firms in the Basel area, where ORYL has been providing measurement services. With the product launch, several of these firms have expressed interest in acquiring the platform directly.
In addition to market validation, ORYL F1 was awarded the Ignite Award at SLAS 2025. The launch follows several years of co-development with key opinion leaders in solubility screening and formulation, reflecting strong user demand for a more efficient and scalable solution.
Based at the Biopôle life sciences campus in Lausanne, ORYL is currently finalizing a fundraising round and expanding its team to support commercialization across Switzerland and Europe.
